Alexion Pharma (ALXN) Tops Q1 EPS by 15c; Raises Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Alexion Reports First Quarter 2017 Results
April 27, 2017 6:30 AM EDT1Q17 Total Revenues of $870 Million, a 24% Increase and 26% Volume Increase Year-Over-Year Revenue Growth Benefited from Continued Strong Volume Growth of Soliris® In Core Markets Strensiq® Revenue Driven by Steady Addition of New Patients Starting Treatment Applications Filed in U.S., Europe and Japan for Soliris in Patients with Refractory gMG Enrollment in ALXN1210 Phase 3 Studies Advanced in Patients with PNH and aHUS New Phase 1 Data Support Advancing Development of ALXN1210 Subcutaneous Formulation Reiterating... More
